March 2018 – Bariatric News

A drug-free approach might be the best treatment we have for America’s most ubiquitous lifestyle disease.

Source: Is Keto the Cure for Type II Diabetes?

Understanding the causes of conflicting outcomes reported using the same cohorts from the MBASQIP PUF data registry May 8, 2021

The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) was created in 2013 when the American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS) combined their respective national bariatric surgery accreditation programs into a unified accreditation program for bariatric surgery centers in the United States and Canada. […]

Anthony T. Petrick, Raul Rosenthal, Craig Wood

Comment to "Long versus short biliopancreatic limb in Roux-en-Y gastric bypass: short-term results of a randomized clinical trial" May 8, 2021

From the early 90’s limb length in Roux-en-Y gastric bypass (RYGB) has been a matter of debate. RYGB remains one of the most efficient bariatric procedures although the mechanisms involved are multifactorial and are still incompletely elucidated. Except for the common channel whose variation in length refers clearly to what has been called “distal gastric […]

Philippe Topart

Authors´ Reply to: Comparing performance of apneic oxygenation methods in morbidly obese patients May 8, 2021

We appreciate the opportunity to comment on the letter to the editor by Bin Hu et al. regarding our manuscript entitled “Duration of safe apnea in patients with morbid obesity during passive oxygenation using high-flow nasal insufflation versus regular flow nasal insufflation, a randomized trial”.

Thomas Hamp, Gerhard Prager, Joanna Baron-Stefaniak, Johannes Müller, Christoph Bichler, Walter Plöchl

Long-term outcome of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR and MC4R gene May 7, 2021

Gene mutations in the leptin-melanocortin signaling cascade are leading to hyperphagia and severe early onset obesity. In most cases, multi-modal conservative treatment (increased physical activity, reduced caloric intake) is not successful to stabilize body weight and control hyperphagia. Therefore, bariatric surgery has been discussed as a therapeutic option for these patients with genetic obesity.

Christine Poitou, Lia Puder, Beatrice Dubern, Philipp Krabusch, Laurent Genser, Susanna Wiegand, Hélène Verkindt, Arvid Köhn, Reiner Jumpertz von Schwartzenberg, Christa Flück, François Pattou, Martine Laville, Peter Kühnen, Karine Clément

The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity May 5, 2021

Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is beneficial for human glucose metabolism, and GLP-1 secretion is greatly enhanced following Roux-en-Y gastric bypass (RYGB).

Pim W. Gilijamse, Ahmet Demirkiran, Bart A. van Wagensveld, Mariette T. Ackermans, Johannes A. Romijn, Max Nieuwdorp, Kasper W. ter Horst, Mireille J. Serlie

Month: March 2018

4 reasons you’re always hungry

Is Keto the Cure for Type II Diabetes?